Cytokinetics makes a commitment to the climate and carries out its carbon assessment
Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, they are developing small molecule drug candidates specifically engineered to impact muscle function and contractility.
1998
Date of creation
424
Number of employees
2021
Year analyzed